Rifaximin, 98%

Name: Rifaximin, 98% | 80621-81-4
Brand: J&K Chemical
SKU: JK286363_5_G
Price: 33.8 USD
Availability: OutOfStock

Cat. No JK286363_5_G

Vendor: J&K Chemical

Product Information

Product Name

Rifaximin, 98%

Brand Name

J&K

Product Number

286363

CAS

80621-81-4

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

6436173

IUPAC Name

(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo23.10.1.14,7.05,35.026,34.027,32heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl acetate

InChI Key

NZCRJKRKKOLAOJ-XRCRFVBUSA-N

SMILES

CC@H1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)OC@@(C4=O)(O/C=C/C@@H(C@H(C@H(C@@H(C@@H(C@@H(C@H1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C

Safety Information

Storage Condition

Store at 2-8℃

References Data Source From Pubchem

Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statement

Publication Name: Hepatology International

Publication Date: 2026-03-03

DOI: 10.1007/s12072-025-11023-x

Impact of IBS on Older Adults: A Narrative and Systematic Review of Diagnostics, Quality of Life Considerations, and Therapies Including Pharmacologic and Non-Pharmacologic

Publication Name: Current Treatment Options in Gastroenterology

Publication Date: 2026-03-03

DOI: 10.1007/s11938-026-00488-w

From Hepatic Encephalopathy to Physiologic Reserve: Rifaximin’s Second Act in Cirrhosis

Publication Name: Digestive Diseases and Sciences

Publication Date: 2026-03-02

DOI: 10.1007/s10620-026-09790-0

Progression rate of diverticular disease and associated risk factors: results from 5-year longitudinal prospective nationwide diverticular disease registry (REMAD)

Publication Name: Internal and Emergency Medicine

Publication Date: 2026-02-26

DOI: 10.1007/s11739-026-04283-4

Novel Approaches to Cirrhosis Prognostication – Recognizing the Role of Albumin, Hepatic Encephalopathy, and Machine-Learning Models

Publication Name: Current Hepatology Reports

Publication Date: 2026-02-26

DOI: 10.1007/s11901-026-00724-y

Rifaximin, 98%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statement

Impact of IBS on Older Adults: A Narrative and Systematic Review of Diagnostics, Quality of Life Considerations, and Therapies Including Pharmacologic and Non-Pharmacologic

From Hepatic Encephalopathy to Physiologic Reserve: Rifaximin’s Second Act in Cirrhosis

Progression rate of diverticular disease and associated risk factors: results from 5-year longitudinal prospective nationwide diverticular disease registry (REMAD)

Novel Approaches to Cirrhosis Prognostication – Recognizing the Role of Albumin, Hepatic Encephalopathy, and Machine-Learning Models

Rifaximin, 98%

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-3-methoxy-L-phenylalanine

2-Ethynyl-1,3,5-trimethylbenzene, 97%

Tris-acetic acid electrophoresis buffer (50×TAE)

[S(R)]-N-[(1S)-1-[2-(Diadamantanphosphino)phenyl]ethyl]-N,2-dimethyl-2-propanesulfinamide, 95%

Mycophenolate Mofetil EP Impurity H

3-(4-Bromo-2-fluoro-3-methoxyphenyl)-3-oxo-propionic acid ethyl ester

Isochroman-1-carboxylic acid

Mycophenolate Mofetil

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Rifaximin, 98%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statement

Impact of IBS on Older Adults: A Narrative and Systematic Review of Diagnostics, Quality of Life Considerations, and Therapies Including Pharmacologic and Non-Pharmacologic

From Hepatic Encephalopathy to Physiologic Reserve: Rifaximin’s Second Act in Cirrhosis

Progression rate of diverticular disease and associated risk factors: results from 5-year longitudinal prospective nationwide diverticular disease registry (REMAD)

Novel Approaches to Cirrhosis Prognostication – Recognizing the Role of Albumin, Hepatic Encephalopathy, and Machine-Learning Models

Rifaximin, 98%

Related Product

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-3-methoxy-L-phenylalanine

2-Ethynyl-1,3,5-trimethylbenzene, 97%

Tris-acetic acid electrophoresis buffer (50×TAE)

[S(R)]-N-[(1S)-1-[2-(Diadamantanphosphino)phenyl]ethyl]-N,2-dimethyl-2-propanesulfinamide, 95%

Mycophenolate Mofetil EP Impurity H

3-(4-Bromo-2-fluoro-3-methoxyphenyl)-3-oxo-propionic acid ethyl ester

Isochroman-1-carboxylic acid

Mycophenolate Mofetil

#title#

Login

Register